Publicaciones en colaboración con investigadores/as de Clínica Universitaria de Navarra (32)

2024

  1. Low-Dose Ionizing γ-Radiation Elicits the Extrusion of Neutrophil Extracellular Traps

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 30, Núm. 18, pp. 4131-4142

  2. MHC class I and II-deficient humanized mice are suitable tools to test the long-term antitumor efficacy of immune checkpoint inhibitors and T-cell engagers

    Journal for immunotherapy of cancer, Vol. 12, Núm. 9

  3. Systemic messenger RNA replacement therapy is effective in a novel clinically relevant model of acute intermittent porphyria developed in non-human primates

    Gut

  4. Tumor slice culture system for ex vivo immunotherapy studies

    Methods in Cell Biology, Vol. 189, pp. 55-69

  5. Unveiling the multifaceted antitumor effects of interleukin 33

    Frontiers in Immunology

2023

  1. Identification and experimental validation of druggable epigenetic targets in hepatoblastoma

    Journal of Hepatology, Vol. 79, Núm. 4, pp. 989-1005

2021

  1. CD137 Costimulation Counteracts TGFβ Inhibition of NK-cell Antitumor Function

    Cancer Immunology Research, Vol. 9, Núm. 12, pp. 1476-1490

  2. IL8, neutrophils, and NETs in a collusion against cancer immunity and immunotherapy

    Clinical Cancer Research, Vol. 27, Núm. 9, pp. 2383-2393

2019

  1. Daratumumab in combination with urelumab to potentiate anti-myeloma activity in lymphocyte-deficient mice reconstituted with human NK cells

    OncoImmunology, Vol. 8, Núm. 7

2018

  1. An Inducible Promoter Responsive to Different Porphyrinogenic Stimuli Improves Gene Therapy Vectors for Acute Intermittent Porphyria

    Human Gene Therapy, Vol. 29, Núm. 4, pp. 480-491

  2. Intratumoral immunotherapy with XCL1 and sFlt3L encoded in recombinant semliki forest virus–derived vectors fosters dendritic cell–mediated t-cell cross-priming

    Cancer Research, Vol. 78, Núm. 23, pp. 6643-6654

  3. Revisiting interleukin-12 as a cancer immunotherapy agent

    Clinical Cancer Research, Vol. 24, Núm. 12, pp. 2716-2718

  4. Systemic messenger RNA as an etiological treatment for acute intermittent porphyria

    Nature Medicine, Vol. 24, Núm. 12, pp. 1899-1909

2016

  1. Emerging therapies for acute intermittent porphyria

    Expert Reviews in Molecular Medicine, Vol. 18

  2. Tumor-Produced Interleukin-8 Attracts human myeloid-derived suppressor cells and elicits extrusion of Neutrophil Extracellular Traps (NETs)

    Clinical Cancer Research, Vol. 22, Núm. 15, pp. 3924-3936

2015

  1. Chronic exposure to IFNα drives medullar lymphopoiesis towards t-cell differentiation in mice

    Haematologica, Vol. 100, Núm. 8, pp. 1014-1022

2014

  1. Harnessing high density lipoproteins to block transforming growth factor beta and to inhibit the growth of liver tumor metastases

    PLoS ONE, Vol. 9, Núm. 5

2013

  1. Cytokines for the treatment of gastrointestinal cancers: Clinical experience and new perspectives

    Expert Opinion on Investigational Drugs, Vol. 22, Núm. 7, pp. 827-841

2011

  1. Characterization of woodchuck apolipoprotein A-I: A new tool for drug delivery and identification of altered isoforms in the woodchuck chronic hepatitis model

    Journal of Medical Virology, Vol. 83, Núm. 7, pp. 1221-1229

  2. Development of a liver-specific tet-on inducible system for AAV vectors and its application in the treatment of liver cancer

    Molecular Therapy, Vol. 19, Núm. 7, pp. 1245-1253